Replies to post #151318 on Biotech Values

[rkrw]

If Ariad quotes Cortes when Ponatinib is approved, we'll have to compare the quotes.
I think his endorsement in the Teva PR comes across as extremely tepid.

“With SYNRIBO, physicians will now have access to another option, offering potential hope to patients who experience treatment failure.”